Unfractionated vs. low-molecular-weight heparin (LMWH): Find out what the difference is and how they work for DVT.

Deep-vein thrombosis occurred in 2.51% of patients in the aspirin group and 1.71% in the low-molecular-weight–heparin group (difference, 0.80 percentage points; 95% CI, 0.28 to 1.31).

The consensus in the American College of Chest Physicians (ACCP) statement published in Chest in 1998 did not recommend routine use of low-molecular-weight (LMW) heparin for outpatient treatment ...

McMaster University. "Low molecular weight heparin use in cancer treatment." ScienceDaily. ScienceDaily, 15 February 2012. <www.sciencedaily.com / releases / 2012 / 02 / 120215185838.htm>.

If both drugs are administered as they were in the study, the cost of a six-day course of low-molecular-weight heparin is about $712, compared with $37 for a similar course of unfractionated ...

Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. 2004;10:632-642. 2.

Low-molecular weight heparin was shown to be as effective as inpatient IV unfractionated heparin management in mechanical heart valve patients requiring interruption of chronic anticoagulation for ...

June 29, 2004 -- Low-molecular-weight heparin can serve as a bridge during warfarin interruption, according to the results of a trial of consecutive patients published in the June 28 issue of the ...

Patients with cancer who had acute, symptomatic proximal deep-vein thrombosis, pulmonary embolism, or both were randomly assigned to receive low-molecular-weight heparin (dalteparin) at a dose of ...

Discover the findings of the ALIFE2 trial on low-molecular-weight heparin (LMWH) use for recurrent pregnancy loss and inherited thrombophilia. The ALIFE2 trial challenges the routine prescription ...